Catalent’s advanced softgel technologies, including lipid-based formulations and emerging plant-based gelatin alternatives, are providing biopharma clients with enhanced options to optimize drug stability, bioavailability, and onset of action. These innovations address challenges such as poor solubility and chemical degradation of sensitive APIs. For example, a BTK inhibitor targeting hematologic malignancies with CNS involvement benefited from softgel encapsulation, improving therapeutic profiles.